New combo therapy aims to wipe out hidden leukemia cells
NCT ID NCT07108998
First seen Jan 07, 2026 · Last updated Jun 09, 2026 · Updated 24 times
Summary
This study tests whether adding the drug epcoritamab after standard treatment can make chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) disappear more completely. About 22 adults who have already received at least 12 months of a BTK inhibitor (acalabrutinib or zanubrutinib) with or without obinutuzumab will receive epcoritamab for 12 cycles. The goal is to see if this approach leads to undetectable minimal residual disease, meaning no cancer cells can be found in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
University of Cincinnati
RECRUITINGCincinnati, Ohio, 45219, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.